FDA Clearance Tracker · P250026
Atellica IM free PSA II (fPSAII)
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this decision)Source: openFDAMethods & limitations
Decided
May 11, 2026
Approved
Time to decision
297 days
Received Jul 18, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250026
- Device name
- Atellica IM free PSA II (fPSAII)
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Applicant location
- Tarrytown, NY
- Received
- Jul 18, 2025
- Decided
- May 11, 2026
- Decision
- Approved
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the Atellica IM free PSA II (fPSAII):The Atellica IM free PSA II (fPSAII) assay is for in vitro diagnostic use in the quantitative measurement of free prostate-specific antigen (fPSA) in human serum and plasma (lithium heparin and EDTA) using the Atellica IM Analyzer. The Atellica IM fPSAII assay is intended to be used in conjunction with the Atellica IM total PSA II (tPSAII) assay in men aged 50 years and older with total prostate-specific antigen (PSA) values between 4 ng/mL (µg/L) and 10 ng/mL (µg/L) and a digital rectal examination (DRE) non-suspicious for cancer to determine the percent free PSA value. The percent free PSA value can be used as an aid in discriminating between prostate cancer and benign prostatic disease. A prostate biopsy is required for the diagnosis of prostate cancer.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MTG. The earliest in FDA's data is P950021, decided Dec 22, 1995.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Siemens Healthcare Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
- Atellica IM CA 19-9 II510(k)
K253528 · Decided Aug 10, 2026 · 270 days after receipt
Device type: System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer (NIG) · Laboratory Medicine & Pathology
K261364 · Decided Jul 24, 2026 · 88 days after receipt
Device type: Colorimetry, Acetaminophen (LDP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.